Similar Search Results

Comparative Effectiveness and Child Health

Prosser, Lisa A. - In: PharmacoEconomics 30 (2012) 8, pp. 637-645

to aspects of health and healthcare that are specific to children. These special considerations include the role of … children represents an exciting opportunity to provide evidence that can guide clinical and policy decisions for child health. …

Persistent link: https://www.econbiz.de/10010556695

Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years: A NICE Single Technology Appraisal

Burch, Jane; Griffin, Susan; McKenna, Claire; Walker, Simon - In: PharmacoEconomics 30 (2012) 11, pp. 991-1004

children with ≥3 exacerbations as baseline. The ERG identified a number of issues relating to the clinical effectiveness …-of-life data collected in adults for children. The ERG concluded that omalizumab appears to reduce CS exacerbations but there was … number of CSS exacerbations avoided was low, as is asthma-related mortality in children, the potential small gain in QALYs …

Persistent link: https://www.econbiz.de/10010579449

Is There a Role for Pharmacoeconomics in Developing Countries?

Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436

Persistent link: https://www.econbiz.de/10011005069

Is There a Role for Pharmacoeconomics in Developing Countries?

Pérez Velasco, Romn Prez Velasco; Teerawattananon, Yot - In: PharmacoEconomics 29 (2011) 5, pp. 433-435

Persistent link: https://www.econbiz.de/10011005082

Exploring Uncertainty in Cost-Effectiveness Analysis

Claxton, Karl - In: PharmacoEconomics 26 (2008) 9, pp. 781-798

This paper describes the key principles of why an assessment of uncertainty and its consequences are critical for the types of decisions that a body such as the UK National Institute for Health and Clinical Excellence (NICE) has to make. In doing so, it poses the question of whether formal...

Persistent link: https://www.econbiz.de/10005243089

NICE Says No to Inhaled Insulin: What Lessons Should We Learn?

Freemantle, Nick - In: PharmacoEconomics 24 (2006) 7, pp. 627-629

Persistent link: https://www.econbiz.de/10005243098

Accounting for Tastes: A German Perspective on the Inclusion of Patient Preferences in Healthcare

Vogt, Florian; Schwappach, David L.B.; Bridges, John F.P. - In: PharmacoEconomics 24 (2006) 5, pp. 419-423

Internationally, there has been a movement in medicine to better involve patients in decision making, whether it be at the individual or aggregate level. However, the German health sector has been slow to understand and accommodate the preferences of patients. This paper discusses the reasons...

Persistent link: https://www.econbiz.de/10005243132

Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer

Simoens, Steven - In: PharmacoEconomics 25 (2007) 3, pp. 181-185

Persistent link: https://www.econbiz.de/10005243170

Common Drug Review Recommendations: An Evidence Base for Expectations?

Rocchi, Angela; Miller, Elizabeth; Hopkins, Robert B.; … - In: PharmacoEconomics 30 (2012) 3, pp. 229-246

Background:Background: The Common Drug Review (CDR) was created to provide a single process to review the comparative clinical efficacy and cost effectiveness of new drugs, and then to make formulary listing recommendations to Canadian publicly funded drug benefit plans. Abstract:...

Persistent link: https://www.econbiz.de/10009493382

Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands

Hoomans, Ties; Severens, Johan L.; van der Roer, Nicole; … - In: PharmacoEconomics 30 (2012) 3, pp. 219-227

Background:Background: In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that...

Persistent link: https://www.econbiz.de/10009493384

1
2
3
4
5
6
7
8
9
10
Next
Last